Lung Cancer: Targets and Therapy (Dec 2019)

Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer

  • Mix M,
  • Tanny S,
  • Nsouli T,
  • Alden R,
  • Chaudhari R,
  • Kincaid R,
  • Rosenbaum PF,
  • Bogart JA,
  • Aridgides P

Journal volume & issue
Vol. Volume 10
pp. 151 – 159

Abstract

Read online

Michael Mix,1 Sean Tanny,1 Tamara Nsouli,1 Ryan Alden,1 Rishabh Chaudhari,2 Russell Kincaid,1 Paula F Rosenbaum,3 Jeffrey A Bogart,1 Paul Aridgides1 1Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA; 2Department of Radiation Oncology, University of Cincinnati/University Hospital Barrett Cancer Center, Cincinatti, OH 45267, USA; 3Department of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY, 13210, USACorrespondence: Michael MixDepartment of Radiation Oncology, SUNY Upstate Medical University, 750 E Adams St, Syracuse, NY 13210, USATel +1 315 464-5276Email [email protected]: The treatment techniques used for stereotactic body radiation therapy (SBRT) for early-stage lung cancer continue to evolve. In this study, clinical outcomes following SBRT were evaluated according to the use of either 3D conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT).Patients and methods: Patients with stage I NSCLC who received SBRT from 2007 to 2015 were retrospectively reviewed. Disease control and survival were assessed using Kaplan-Meier estimates. Dosimetric analyses for target dose heterogeneity and coverage were performed.Results: A total of 297 patients with 351 lesions were included. 3DCRT was used in 52% and IMRT in 48%. IMRT was utilized at a higher rate in more recent years. The most common regimens were 48 Gy in 4 fractions and 54–60 Gy in 3 fractions. With a median follow up of 22.7 months, there were 17 local failures for a crude relapse rate of 5.7%. Local failure did not differ in patients treated with 3DCRT and IMRT (4.9% vs 6.5%, p=0.573). Mean dose to gross tumor volume (GTV) as a percent of prescription dose was higher with 3DCRT compared with IMRT (107.7% vs 103.6%, p < 0.0001). Tumor stage, histology, and SBRT regimen did not correlate with local tumor control. Overall survival for the entire population approximated 72% at 2 years. Treatment was well tolerated with 6 documented grade 3+ events.Conclusion: In this single-institution cohort of SBRT for early-stage NSCLC, there was no discernible difference in clinical outcomes between those treated with 3DCRT and IMRT.Keywords: SBRT, IMRT, stereotactic ablative radiation therapy, SABR, radiotherapy

Keywords